Recombinant Human UDP-glucuronosyltransferase 2B15 (UGT2B15), partial

1. High UGT2B15 expression is associated with the pathogenesis of gastric cancer. PMID: 30066917
2. Results found no significant increased risk for benign prostatic hyperplasia (BPH) in men with low activity genotype at D85Y, but found rather, a significant association between UGT2B15 D85Y and BPH risk when it is in combination with the UGT2B17 copy number variation. PMID: 28882566
3. the UGT2B15 and UGT2B17 enzymes are transcriptionally regulated by sex hormone signaling in ERalpha+ breast cancer cells and are highly expressed in a subset of primary breast cancers. PMID: 27496708
4. UGT2B15 genotype contributes to postoperative anxiety reduction after lorazepam premedication. PMID: 27622723
5. Report frequency of UGT2B15 genetic polymorphisms in Pakistani population and genotype/phenotype correlation for glucuronidation of paracetamol. PMID: 27383482
6. CYP3A4, CYP3A7, UGT2B11 and UGT2B15 genes are significantly downregulated in melanosis coli. PMID: 26238215
7. miR-376c is inversely linked to UGT2B15 and UGT2B17 expression in high-grade prostate cancer and metastasis.UGT2B15 and UGT2B17 genes are direct targets of miR-376c and thus may influence steroid metabolism during prostate cancer progression. PMID: 26385605
8. Data suggest that both 17beta-estradiol and the antiestrogen 4-OHTAM (4-hydroxytamoxifen, a metabolite of tamoxifen and substrate of UGT2B15) up-regulate UGT2B15 in breast cancer cells via the same estrogen receptor alpha- (ERa-)signaling pathway. PMID: 25795461
9. Hepatic UGT2B15 protein onset begins in late gestation; however, the greatest rate of change occurs during the first few weeks after birth. PMID: 24980262
10. Expression of UGT2B15 and UGT2B17 is negatively regulated by the binding of miR-376c. PMID: 26163549
11. UGT2B15 genotype is a major determinant for differences in fasting plasma glucose and HbA1c response to sipoglitazar treatment between Type 2 Diabetes mellitus patients, due to related differences in drug exposure. PMID: 24214217
12. A haplotype in UGT2B15 containing a functional variant (rs4148269, K523T) and an intronic SNP (rs6837575) was found to affect rectal cancer risk overall (OR = 2.57, 95% CI = 1.21-5.04) and in females (OR = 3.08, 95% CI = 1.08-8.74). PMID: 24822274
13. In the tamoxifen-treated subgroup poor prognosis was related to the combined presence of ESR1 PvuII wt/wt and UGT2B15 wt/wt or wt/*2 genotype. PMID: 23951298
14. Novel associations between UGT2B15 and UGT2B17 single nucleotide polymorphism variants and prostate cancer risk. PMID: 24267955
15. UGT2B15 is a possible target for androgen deprivation therapy of prostate cancer. PMID: 24121496
16. Report the influence of functionally relevant polymorphic UGT2B15, the enzyme mediating bisphenol A metabolism using kinetic based modelling. PMID: 23404680
17. Sipoglitazar clearance is substantially modified by UGT2B15 enzyme variants, with higher exposure observed in the UGT2B15*2/*2 genotype group. PMID: 22960998
18. Report UGT2B15 expression in fetal/adult tissues. PMID: 23223495
19. Data indicates that 2B15 requires regulated phosphorylation by both PKCalpha and Src, which is consistent with the complexity of synthesis and metabolism of its major substrate, DHT. PMID: 22532564
20. The study revealed that UGT2B15 and UGT2B17 are differentially regulated during prostate cancer progression. PMID: 22170718
21. For UGT2B15, the percentage of APAPG decreased (P < 0.0001) and that of APAP sulfate increased (P = 0.002) in an allelic dose-dependent manner across genotypes from *1/*1 to *2/*2. PMID: 21666065
22. The D85Y substitution in UGT2B15 decreases enzymatic function, and the polymorphic alleles of UGT2B15 are closely associated with variations in the metabolism and toxicity of bisphenol A. PMID: 21404072
23. Data show that steroidogenic enzymes (AKR1C3, HSD17B2, UGT2B15 and UGT2B17) and stem/progenitor cell markers CK5 and ABCG2 were upregulated in castration resistant prostate cancer. PMID: 21365123
24. regulation of the UGT2B15 and UGT2B17 genes by FOXA1 may have an important role in the maintenance of androgen homeostasis within prostate cancer cells. PMID: 20736324
25. SNPs in strong linkage disequilibrium with G253T regulate UGT2B15 expression in liver. PMID: 19847790
26. UGT2B15 polymorphism cannot be considered as a susceptibility marker for prostate cancer, but it involoved in glucuronidation of numerous phytochemicals. This polymorphism could contribute to interindividual variability in chemopreventive effects. PMID: 12010866
27. Single-nucleotide polymorphisms (SNPs) were found in UGT2B15 gene PMID: 12376738
28. The alteration of UGT2B15 expression in LNCaP-SF cells is proposed as a biological characteristic involved in the growth of hormone-refractory prostate cancer. PMID: 12646996
29. Although D85 and Y85 appear to be common variants, we cannot exclude the possibility that the UGT2B15 gene represents a minor modifying locus. PMID: 12880121
30. In human prostate, UGT2B15 and UGT2B17 genes have complementary roles and are expressed in cells where their specific substrates are synthesized. PMID: 15666817
31. Tamoxifen-treated patients with UGT2B15 high activity genotypes had increased risk of recurrence PMID: 15952058
32. estrogen-induced up-regulation of UGT2B15 might have a significant moderating effect on estrogen and androgen concentrations, thereby reducing their signaling in breast cancer cells PMID: 16690804
33. 5-(4'-Hydroxyphenyl)-5-phenylhydantoin O-glucuronide formation in human liver microsomes is catalyzed by UGT1A1, UGT1A9, and UGT2B15 in a stereoselective manner PMID: 17576806
34. UGT2B15 and -B17 are critical enzymes for the local inactivation of androgens and that glucuronidation is a major determinant of androgen action in prostate cells PMID: 17848572
35. Androsterone reduces the glucuronidation of androgens catalysed by UGT2B15 and UGT2B17 in a prostate tumor cell line. PMID: 17988216
36. Vitamin D receptor activator calcitriol as a negative regulator of the UGT2B15- and UGT2B17-dependent inactivation of androgens in prostate cancer LNCaP cells. PMID: 18281521
37. UGT2B15 ia a primary androgen-regulated genes and androgen receptor is required for basal expression and androgen-regulated expression. PMID: 18302198
38. Estrogen receptor alpha, fos-related antigen-2, and c-jun coordinately regulate human UGT2B15 expression in response to 17beta-estradiol in MCF-7 cells. PMID: 19487245
39. UGT2B15 functional polymorphism along with Copy-number variations PMID: 19572376
40. Clinical trial of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 17244352
41. Gender and UGT2B15 D85Y genotype are identified as major determinants of S-oxazepam glucuronidation by human liver and may explain in part polymorphic oxazepam glucuronidation by human subjects. PMID: 15044558
42. S-oxazepam is stereoselectively glucuronidated by UGT2B15, whereas R-oxazepam is glucuronidated by multiple UGT isoforms. Allelic variation associated with the UGT2B15 gene may explain polymorphic S-oxazepam glucuronidation in humans. PMID: 12386133

Show More

Hide All

HGNC: 12546

OMIM: 600069

KEGG: hsa:7366

STRING: 9606.ENSP00000341045

UniGene: Hs.150207